Harvard College v Canada (Commissioner of Patents)

Last updated
Harvard College v Canada (Commissioner of Patents)
Supreme court of Canada in summer.jpg
Supreme Court of Canada
Hearing: May 21, 2002
Judgment: December 5, 2002
Full case nameCommissioner of Patents v. President and Fellows of Harvard College
Citations 2002 SCC 76, 219 D.L.R. (4th) 577, 21 C.P.R. (4th) 417, [2004] 235 F.T.R. 214
Docket No.28155 [1]
Prior historyJudgment for Harvard from the Federal Court of Appeal.
RulingGov't appeal allowed
Holding
Higher life-forms are not patentable under the meaning of "invention" in section 2 of the Patent Act
Court membership
Chief Justice: Beverley McLachlin
Puisne Justices: Claire L'Heureux-Dubé, Charles Gonthier, Frank Iacobucci, John C. Major, Michel Bastarache, Ian Binnie, Louise Arbour, Louis LeBel
Reasons given
MajorityBastarache J., joined by L'Heureux-Dubé, Gonthier, Iacobucci, and LeBel JJ.
DissentBinnie J., joined by McLachlin, Major, Arbour JJ.

Harvard College v Canada (Commissioner of Patents) [2] is a leading Supreme Court of Canada case concerning the patentability of higher life forms within the context of the Patent Act. [3] At issue was the patentability of the Harvard oncomouse, a mouse that had its genome genetically altered by a cancer-promoting gene (oncogene). In a 5-4 split, the Supreme Court held that the oncomouse and higher life forms in general are not patentable subject matter in Canada.

Contents

Background

Harvard College researchers (the respondents) developed a process by which they could create transgenic animals whose genomes are altered by a cancer-promoting gene (called an activated oncogene). [4] The researchers injected the oncogene into fertilized mouse eggs close to the one-cell stage and implanted them into a female host mouse where they developed to term. [5] The resulting offspring were then tested for the presence or absence of the oncogene. [5] Those with the gene are referred to as "founder" mice and are mated with unaltered mice. [5] Offspring that contain the oncogene and have every cell in their body affected (including germ cells and somatic cells) by it are referred to as oncomice. Oncomice are useful for carcinogenic studies as they are more susceptible to carcinogens. [6] Such mice can be given material suspected of being a carcinogen and if tumours develop, it is an indication that the material is carcinogenic. [6]

Initial Patent Application and Trial

In 1985, the President and Fellows of Harvard College applied for a patent for an invention called "transgenic animals." [6] In particular, they applied for a process patent for the process by which they created the mice as well as a product patent for the end product of the process, namely the "founder" mice and the oncomice, offspring whose cells are affected by the gene. [4] These patent claims also extend to all non-human mammals whose genomes have been altered in a similar manner. [4] Patent applications on the oncomouse were filed in many countries including the United States, Canada, Europe (through the European Patent Office) and Japan.

In March 1993, the Patent Examiner rejected the product claims (Claims 1 to 12) on the grounds that higher life forms were outside the definition of "invention" in section 2 of the Canadian Patent Act [7] and are therefore not patentable subject matter. [8] The process claims (Claims 13 to 26) were allowed. [9] In August 1995, the Commissioner of Patents and the Patent Appeal Board upheld the refusal to grant a patent for the product claims. [10] This decision was upheld by the Federal Court, Trial Division, [11] but was overturned by a majority of the Federal Court of Appeal. [11] The Commissioner of Patents appeals from that decision.

Federal Court of Appeal

The majority of the court reversed the decision of the Federal Court and directed the Commissioner of Patents to issue a patent covering claims 1 to 12 of the Patent Application. Speaking for the majority, Rothstein J.A. emphasized the object of the Patent Act, which is to "promote the development of inventions in a manner that benefits both the inventor and the public." [12] He stated that the Commissioner has no discretion to refuse to grant a patent under s.40 of the Act and if a process or product satisfies the requirements of the Act, a patent must be granted. [13] Additionally, the Patent Act does not explicitly exclude living organisms such as non-human mammals from the definition of "invention." [14] The majority concluded that the oncomouse "must be considered to be the result of both ingenuity and the laws of nature" [15] and is an invention within the meaning of s.2 of the Patent Act, as it is both unobvious and a new and useful "composition of matter." [16]

Isaac J.A. in dissent, approved of the approach taken by the Patent Examiner and concluded that the Commissioner of Patents must be aware of and take into consideration the public interest. [17] He states that in a morally divisive case such as the one at hand, the court should defer to the Commissioner's decision to refuse to grant a patent. [17]

Leave was granted to the Supreme Court on June 14, 2001.

Supreme Court Ruling

The court found in favour of the government, ruling that higher life forms are not patentable. The opinion of the court was written by Bastarache J. with L'Heureux-Dubé, Gonthier, Iacobucci, and LeBel JJ. concurring. The sole question before the court was whether the words "manufacture" or "composition of matter," in the context of the Patent Act, are broad enough to encompass higher life forms such as the oncomouse. [18] The court found that they are not. Bastarache J. stated that the determination of the patentability of higher life forms such as the oncomouse is beyond the authority of the court and would be a massive change in the current patent regime. The majority indicated that as there are significant public policy concerns at play, Parliament is best suited to address this issue. [19]

The Commissioner’s Power to Refuse a Patent under Section 40

Though the court believed that the Commissioner went beyond his powers in ruling against a patent on public policy reasons, the court came to the same conclusion in denying the patentability of higher life forms such as the oncomouse. The majority stated that s.40 of the Patent Act does not give the Commissioner any discretion to refuse to grant a patent on the basis of public policy considerations, echoing Pigeon J.’s statement in Monsanto Co. v. Commissioner of Patents. [20] In terms of the standard of review, the majority believed that the question of whether higher life forms are included in the definition of "invention" in the Patent Act is reviewable on a correctness standard. [21]

The Definition of "Invention": Whether a Higher Life Form Is a "Manufacture" or a "Composition of Matter"

(a) The Words of the Act

In s.2, the Patent Act defines an "invention" as "any new and useful art, process, machine, manufacture or composition of matter, or any new and useful improvement in any art, process, machine, manufacture or composition of matter." [7] The majority concluded that although the definition of "invention" is broad, it does not include "anything under the sun that is made by man." [22]

The majority held that the words "manufacture" and "composition of matter" are not sufficiently broad to include a higher life form such as the oncomouse. [23] The court is of the opinion that "manufacture" denotes "a non-living mechanistic product or process" [24] and does not imply a conscious, sentient living creature. [25] The majority determined that the meaning of "composition of matter" can be ascertained by reference to the meaning of the words or phrases associated with them and thus is best read as not including higher life forms. [26] The majority also referred to the Oxford English Dictionary definition of "composition" which is "a substance or preparation formed by combination or mixture of various ingredients" and concluded that the oncomouse cannot be understood in such terms. [27] They also emphasized that higher life forms have unique qualities and characteristics that transcend the particular genetic matter of which they are composed. [28]

More generally, the court is of the opinion that allowing patents on higher life forms would involve "a radical departure from the traditional patent regime" and it is for to Parliament to determine whether higher life forms are patentable. [29]

(b) The Scheme of the Act

The majority determined that the Patent Act, in its current form, is "ill-equipped to deal appropriately with higher life forms as patentable subject matter" since biological life forms are living, capable of self-replication, incredibly complex, incapable of full description, and can contain important characteristics having nothing to do with the invention. [30] Justice Bastarache identified some of the serious issues surrounding the patentability of higher life forms including: the agricultural impact on farmers who wish to save and reuse seeds, [31] the rights of the "innocent bystander," who may come into possession of a patented organism by virtue of its ability to self-replicate and thus be subject to an infringement action, [32] deterrence of biomedical research and innovation, [33] and the potential for the commodification of human life, tissues and organs. [34]

(c) The Object of the Act

The majority stated that the two central objects of the Patent Act are "to advance research and development and to encourage broader economic activity." [35] Although those are broad objectives, they determined that Parliament did not leave the definition of "invention" open and neither the language nor scheme of the Act suit higher life forms. [36] Thus, they held that Parliament did not intend to extend Patent monopoly rights over inventions related to higher life forms. [36]

The majority used the fact that Parliament enacted the Plant Breeders’ Rights Act in the wake of the Supreme Court's decision in Pioneer Hi-Bred Ltd. v. Commissioner of Patents [37] to bolster their view that Parliament did not believe the Patent Act was tailored to include higher life forms. [38] Bastarache J. stated that since Parliament enacted specialized legislation to deal with the issues surrounding crossbred plants, a subset of higher life forms, had they wished to extend patentability to other higher life forms, they would have likely done so at the time. [39]

Drawing the Line: Is it Defensible to Allow Patents on Lower Life Forms While Denying Patents on Higher Life Forms?

In response to the respondent's argument that drawing a line between lower and higher life forms is indefensible, Justice Bastarache stated that the line is "defensible on the basis of common sense differences between the two" and reiterates that a parliamentary response is necessary. [40] Moreover, he stated that the distinction can also be upheld because, unlike higher life forms, a lower life form can more easily be conceptualized as a "composition of matter" or "manufacture" [41] and microbes can be mass-produced like chemical compounds and will possess uniform properties and characteristics. [42]

Dissent

A dissent written by Binnie J., with McLachlin C.J., Arbour, and Major JJ. concurring, agreed with the reasoning of the Federal Court of Appeal and were of the opinion that the engineered oncomouse is an "extraordinary scientific achievement" and an inventive "composition of matter" within the meaning of s.2 of the Patent Act. [43] Additionally, Binnie J. stated that other jurisdictions with comparable legislation including the United States, Europe, Japan and New Zealand, among others, have held the oncomouse to be patentable. [44]

Binnie J. disagreed with the view of the Commissioner of Patents that at the time the Patent Act was enacted Parliament could not have intended genetically engineered higher life forms to be patentable. [45] He stated that Parliament could not have contemplated many other future inventions including genetically engineered lower life forms, moon rockets, antibiotics, telephones, e-mail or hand-held computers." [46] He argued that the Patent Act does not distinguish between higher and lower life forms and such a distinction is an invention of the Patent Office. [47] He stated that efforts to draw the line between patentable lower life forms and "unpatentable" higher life forms highlight the arbitrariness of the approach. [48]

Justice Binnie stated that once it is conceded that the genetically altered oncomouse egg meets the criteria for patentability; there is no reason for denying patentability to the resulting oncomouse on the basis that it is not an "invention" as defined by the Patent Act. [49] He stressed that s.40 of the Patent Act does not give the Commissioner discretion to refuse a patent on public policy considerations. [50] Additionally, Binnie J. emphasized the fact that Parliament has repealed and avoided including provisions in the Patent Act dealing with the morality of inventions as an indication that these aspects of public policy should be dealt using other regulatory regimes. [51] He identified the Assisted Human Reproduction Act [52] as an example of specialized legislated enacted to deal with public policy considerations similar to the ones at play in this case. [53]

Controversy

Justice Binnie noted that the outcome of this case takes Canada on a very different trajectory than other countries, including the United States, Japan and Europe. [54] This fact has led some to argue that there is a risk that biotechnology investment will be reduced in the aftermath of the decision. [55]

The majority's reasoning in drawing the line between higher and lower life forms was called by Dan Burk a "rationally indefensible distinction." [56] He also said that the majority's conclusion that higher but not lower organisms are made of something other than a composition of matter is an "inexplicable reliance on vitalism" and "more properly a matter of religion than a matter of law." [56]

Wendy Adams has found controversy in the court's belief in ethical neutrality in relation to animal welfare under the Canadian patent system. This idea is based on the idea that patents are fully constituted property rights, providing patentees with a default level of entitlement and would undoubtedly "skew the utilitarian calculus of animal welfare to the advantage of human animals and to the detriment of non-human animals." [57] For that reason, Adams wrote that the ethical review of the treatment of animals should be an additional criterion for patentability. [58] Abraham Drassinower has written that animal welfare issues that may arise in the course of patent applications are based on the fact that animals are considered property and these issues are best dealt with outside the confines of the Patent Act. [59]

See also

Related Research Articles

The OncoMouse or Harvard mouse is a type of laboratory mouse that has been genetically modified using modifications designed by Philip Leder and Timothy A Stewart of Harvard University to carry a specific gene called an activated oncogene. The activated oncogene significantly increases the mouse's susceptibility to cancer, and thus makes the mouse a suitable model for cancer research.

<i>Monsanto Canada Inc v Schmeiser</i> Supreme Court of Canada decision

Monsanto Canada Inc v Schmeiser [2004] 1 S.C.R. 902, 2004 SCC 34 is a leading Supreme Court of Canada case on patent rights for biotechnology, between a Canadian canola farmer, Percy Schmeiser, and the agricultural biotechnology company Monsanto. The court heard the question of whether Schmeiser's intentionally growing genetically modified plants constituted "use" of Monsanto's patented genetically modified plant cells. By a 5-4 majority, the court ruled that it did. The Supreme Court also ruled 9-0 that Schmeiser did not have to pay Monsanto their technology use fee, damages or costs, as Schmeiser did not receive any benefit from the technology. The case drew worldwide attention and is widely misunderstood to concern what happens when farmers' fields are accidentally contaminated with patented seed. However, by the time the case went to trial, all claims of accidental contamination had been dropped; the court only considered the GM canola in Schmeiser's fields, which Schmeiser had intentionally concentrated and planted. Schmeiser did not put forward any defence of accidental contamination.

<i>Gosselin v Quebec (AG)</i> Canadian claim for a right to social assistance

Gosselin v Quebec (AG) [2002] 4 SCR 429, 2002 SCC 84, is the first claim under section 7 of the Canadian Charter of Rights and Freedoms to a right to an adequate level of social assistance. The Supreme Court of Canada rejected the Charter challenge against a Quebec law excluding citizens under age 30 from receiving full social security benefits.

<span class="mw-page-title-main">Ian Binnie</span> Justice of the Supreme Court of Canada from 1998 to 2011

William Ian Corneil Binnie is a former puisne justice of the Supreme Court of Canada, serving from January 8, 1998 to October 27, 2011. Of the justices appointed to the Supreme Court in recent years, he is one of the few appointed directly from private practice. On his retirement from the Court, he was described by The Globe and Mail as "arguably the country's premier judge", by La Presse as "probably the most influential judge in Canada of the last decade" and by the Toronto Star as “one of the strongest hands on the court.”

<i>Apotex Inc v Wellcome Foundation Ltd</i> Supreme Court of Canada case

Apotex Inc v Wellcome Foundation Ltd, [2002] 4 S.C.R. 153, is a leading Supreme Court of Canada decision on the utility requirement for a patent in Canada. The Court rejected a challenge by the generic drug manufacturers Novopharm and Apotex to declare Glaxo Wellcome's patent for AZT, an AIDS-fighting drug, invalid.

<i>Syndicat Northcrest v Amselem</i> Supreme Court of Canada case

Syndicat Northcrest v Amselem [2004] 2 S.C.R. 551 was a decision of the Supreme Court of Canada that attempted to define freedom of religion under the Quebec Charter of Human Rights and Freedoms and section 2 of the Canadian Charter of Rights and Freedoms. Although the Supreme Court split on their definition, the majority advocated tolerating a practice where the individual sincerely feels it is connected to religion, regardless of whether the practice is required by a religious authority.

<span class="mw-page-title-main">Canadian patent law</span>

Canadian patent law is the legal system regulating the granting of patents for inventions within Canada, and the enforcement of these rights in Canada.

In United States patent law, a composition of matter is one of the four principal categories of things that may be patented. The other three are a process, a machine, and an article of manufacture. In United States patent law, that same terminology has been in use since the first patent act in 1790.

<i>Dunsmuir v New Brunswick</i> Canadian Supreme Court case

Dunsmuir v New Brunswick, 2008 SCC 9, [2008] 1 SCR 190 was, prior to Canada v Vavilov, the leading Supreme Court of Canada decision on the topic of substantive review and standards of review. Dunsmuir is notable for combining the reasonableness (simpliciter) and the patent unreasonableness standards of review into a single reasonableness standard.

<i>Canada (Minister of Citizenship and Immigration) v Khosa</i> Supreme Court of Canada case

Canada v. Khosa, 2009 SCC 12, is a leading Supreme Court of Canada decision in Canadian administrative law.

<i>Whiten v Pilot Insurance Co</i> Supreme Court of Canada case

Whiten v Pilot Insurance Co, 2002 SCC 18, [2002] 1 S.C.R. 595 is a leading Supreme Court of Canada decision on the availability of punitive damages in contract. The case related to the oppressive conduct of an insurance company in dealing with the policyholders' claim following a fire. According to the majority, "[t]his was an exceptional case that justified an exceptional remedy."

<span class="mw-page-title-main">Sufficiency of disclosure in Canadian patent law</span>

In Canada, every patent application must include the “specification”. The patent specification has three parts: the disclosure, the claims, and the abstract. The contents of the specification are crucial in patent litigation.

<span class="mw-page-title-main">Defences and remedies in Canadian patent law</span>

A patent holder in Canada has the exclusive right, privilege and liberty to making, constructing, using and selling the invention for the term of the patent, from the time the patent is granted. Any person who does any of these acts in relation to an invention without permission of the patent owner is liable for patent infringement.

<span class="mw-page-title-main">Subject matter in Canadian patent law</span>

In Canadian patent law, only “inventions” are patentable. Under the Patent Act, only certain categories of things may be considered and defined as inventions. Therefore, if a patent discloses an item that fulfills the requirements of novelty, non-obviousness and utility, it may nonetheless be found invalid on the grounds that it does not fall within one of the statutory categories of “invention”. Since the Patent Act, the categories of patentable subject matter have been defined and interpreted by Canadian courts.

<i>Tennessee Eastman Co v Canada (Commissioner of Patents)</i> Supreme Court of Canada case

Tennessee Eastman Co v Canada (Commissioner of Patents), [1974] S.C.R. 111, is a leading Supreme Court of Canada authority for the proposition that medical or therapeutic methods are not patentable in Canada.

<i>Canadian Union of Public Employees v Ontario (Minister of Labour)</i> Supreme Court of Canada case

Canadian Union of Public Employees v Ontario (Minister of Labour), 2003 SCC 29, is a leading Supreme Court of Canada decision on arbitration and bias in administrative law. The court held that it was patently unreasonable for the Minister of Labour to appoint retired judges as arbitrators in labour disputes without considering their expertise in labour relations under the Hospital Labour Disputes Arbitrations Act.

<i>Euro-Excellence Inc v Kraft Canada Inc</i> Supreme Court of Canada case

Euro-Excellence Inc v Kraft Canada Inc, 2007 SCC 37, [2007] 3 S.C.R. 20, is a Supreme Court of Canada judgment on Canadian copyright law, specifically on the issue of indirect infringement and its application to parallel importation. Kraft Canada sued Euro-Excellence Inc. for copyright infringement due to their importation of Côte d’Or and Toblerone chocolate bars from Europe into Canada. A majority of the court found that the copyright claim could not succeed, although they split on whether the claim failed due to the rights of an exclusive licensee or due to the scope of copyright law.

Amazon.com Inc v Canada is a decision of the Federal Court of Appeal concerning the patentability of business methods within the context of the Patent Act. At issue was the patentability of a method that allowed customers shopping online to make purchases with one-click buying.

Neither computers nor software are specifically mentioned in the Canadian Patent Act. Canadian courts have held that the use of a computer in an invention neither lends, nor reduces patentability. Therefore, that an invention involves a computer is not determinative of patentability; instead, whether a computer-using invention is patentable turns on whether that invention meets the general requirements for patentability as would apply to any invention.

A biological patent is a patent on an invention in the field of biology that by law allows the patent holder to exclude others from making, using, selling, or importing the protected invention for a limited period of time. The scope and reach of biological patents vary among jurisdictions, and may include biological technology and products, genetically modified organisms and genetic material. The applicability of patents to substances and processes wholly or partially natural in origin is a subject of debate.

References

  1. ↑ SCC Case Information - Docket 28155 Supreme Court of Canada
  2. ↑ Harvard College v Canada (Commissioner of Patents), [2002] 4 SCR 45, 2002 SCC 76
  3. ↑ Patent Act, RSC 1985, c P-4
  4. 1 2 3 Harvard College [2002] 4 SCR 45 at para 123
  5. 1 2 3 Harvard College [2002] 4 SCR 45 at para 122
  6. 1 2 3 Harvard College [2002] 4 SCR 45 at para 121
  7. 1 2 Patent Act, RSC 1985, c P-4, s.2.
  8. ↑ Harvard College [2002] 4 SCR 45 at para 126
  9. ↑ Harvard College [2002] 4 SCR 45 at para 125
  10. ↑ Harvard College [2002] 4 SCR 45 at paras 130
  11. 1 2 Harvard College [2002] 4 SCR 45 at para 135
  12. ↑ President and Fellows of Harvard College v. Canada (Commissioner of Patents), [2000] 4 FC 528 at para 106
  13. ↑ Harvard College [2000] 4 FC 528 at para 109
  14. ↑ Harvard College [2000] 4 FC 528 at para 123
  15. ↑ Harvard College [2000] 4 FC 528 at para 129
  16. ↑ Harvard College [2000] 4 FC 528 at para 114
  17. 1 2 Harvard College [2000] 4 FC 528 at para 54
  18. ↑ Harvard College [2002] 4 SCR 45 at para 146
  19. ↑ Harvard College [2002] 4 SCR 45 at para 153
  20. ↑ Monsanto Co. v. Commissioner of Patents, [1979] 2 S.C.R. 1108 at para 144
  21. ↑ Harvard College [2002] 4 SCR 45 at paras 148-150
  22. ↑ Harvard College [2002] 4 SCR 45 at para 158
  23. ↑ Harvard College [2002] 4 SCR 45 at para 155
  24. ↑ Harvard College [2002] 4 SCR 45 at para 159
  25. ↑ Harvard College [2002] 4 SCR 45 at para 160
  26. ↑ Harvard College [2002] 4 SCR 45 at para 161
  27. ↑ Harvard College [2002] 4 SCR 45 at para 162
  28. ↑ Harvard College [2002] 4 SCR 45 at para 163
  29. ↑ Harvard College [2002] 4 SCR 45 at para 166
  30. ↑ Harvard College [2002] 4 SCR 45 at paras 167 and 184
  31. ↑ Harvard College [2002] 4 SCR 45 at para 171
  32. ↑ Harvard College [2002] 4 SCR 45 at para 172
  33. ↑ Harvard College [2002] 4 SCR 45 at para 173
  34. ↑ Harvard College [2002] 4 SCR 45 at paras 176-182
  35. ↑ Harvard College [2002] 4 SCR 45 at para 185
  36. 1 2 Harvard College [2002] 4 SCR 45 at para 187
  37. ↑ [1987] 3 F.C. 8
  38. ↑ Harvard College [2002] 4 SCR 45 at para 189
  39. ↑ Harvard College [2002] 4 SCR 45 at para 193
  40. ↑ Harvard College [2002] 4 SCR 45 at para 199
  41. ↑ Harvard College [2002] 4 SCR 45 at paras 201 and 203
  42. ↑ Harvard College [2002] 4 SCR 45 at para 202
  43. ↑ Harvard College [2002] 4 SCR 45 at para 8
  44. ↑ Harvard College [2002] 4 SCR 45 at paras 2 and 34
  45. ↑ Harvard College [2002] 4 SCR 45 at paras 9 and 79
  46. ↑ Harvard College [2002] 4 SCR 45 at para 9
  47. ↑ Harvard College [2002] 4 SCR 45 at para 47
  48. ↑ Harvard College [2002] 4 SCR 45 at paras 52-53
  49. ↑ Harvard College [2002] 4 SCR 45 at paras 85-86
  50. ↑ Harvard College [2002] 4 SCR 45 at para 40
  51. ↑ Harvard College [2002] 4 SCR 45 at paras 11, 14, 15, 82, 83 and 90
  52. ↑ Assisted Human Reproduction Act, S.C. 2004, c.2
  53. ↑ Harvard College [2002] 4 SCR 45 at paras 93
  54. ↑ Harvard College [2002] 4 SCR 45 at paras 2, 33-38
  55. ↑ Garland, Steven B. and Smordin, Sandee, Harvard Mouse Decision and Its Future Implications, The Symposium on the Harvard Mouse Decision of the Supreme Court of Canada, 39 Can. Bus. L. J. (2003) at p. 175
  56. 1 2 Burk, Dan L., Reflections in a Darkling Glass: A Comparative Contemplation of the Harvard College Decision Symposium on the Harvard Mouse Decision of the Supreme Court of Canada, 39 Can. Bus. L. J. at p. 221
  57. ↑ Adams, W. A., Myth of Ethical Neutrality: Property, Patents, Animal Rights and Animal Welfare in Commissioner of Patents v. President and Fellows of Harvard College, The Symposium on the Harvard Mouse Decision of the Supreme Court of Canada, 39 Can. Bus. L. J. (2003) at p. 213
  58. ↑ Adams, W. A., Myth of Ethical Neutrality: Property, Patents, Animal Rights and Animal Welfare in Commissioner of Patents v. President and Fellows of Harvard College, The Symposium on the Harvard Mouse Decision of the Supreme Court of Canada, 39 Can. Bus. L. J. (2003)
  59. ↑ Drassinower, Abraham, Property, Patents and Ethics: A Comment on Wendy Adams' "The Myth of Ethical Neutrality" Symposium on the Harvard Mouse Decision of the Supreme Court of Canada, 39 Can. Bus. L. J. (2003)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.